Question 1 · Hard
Metastatic castration-resistant prostate cancer in a retired teacher is progressing despite enzalutamide and six cycles of docetaxel. PSMA PET-CT shows intense uptake in multiple bone and nodal lesions, and FDG PET shows no lesion without PSMA uptake. Haemoglobin is 11.2 g/dL, platelets 190,000/µL and creatinine 0.9 mg/dL. Which treatment is most appropriate?
- ALu-177 DOTATATE therapy
- BLu-177 PSMA radioligand therapy
- CI-131 MIBG therapy
- DRadioiodine (I-131) therapy
Show answerHide answer
Answer: B · Lu-177 PSMA radioligand therapy
Theranostics pairs a diagnostic PSMA PET with a therapeutic beta-emitter aimed at the same target. In PSMA-positive metastatic castration-resistant prostate cancer after an androgen-receptor pathway inhibitor and a taxane, Lu-177 PSMA-617 prolonged survival in the VISION trial. Adequate marrow and kidney function are needed, because these and the salivary glands are the main organs at risk. Key point: PSMA-avid mCRPC after an ARPI and a taxane is treated with Lu-177 PSMA radioligand therapy.
- A: Lu-177 DOTATATE targets somatostatin receptors in neuroendocrine tumours.
- C: MIBG therapy targets neuroblastoma and phaeochromocytoma.
- D: Prostate cancer does not take up iodine.